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Propafenone was administered during electrophysiologic
testing to determine its efficacy and safety for termi-
nating and preventing reinduction of paroxysmal supra-
ventricular reentrant tachycardia. Four men and 10
women (mean age 50 years, range 28 to 69) were studied.
Five patients had Wolff·Parkinson-White syndrome with
orthodromic atrioventricular (AV) reentrant tachycar-
dia, three had a concealed accessory pathway with AV
reentrant tachycardia and six had tachycardia due to
reentry within the AV node.
In the five patients with Wolff-Parkinson-White syn-
drome, propafenone terminated reentrant tachycardia
in three (the tachycardia was reinducible in one) and
had no effect in lWO. In the three patients with a con-
cealed accessory pathway, propafenone terminated reen-
trant tachycardia in all three and prevented reinduction
of the tachycardia in two. In the six patients with tachy-
cardia due to reentry within the AV node, propafenone
terminated and prevented reinduction of reentrant
Propafenone, a class lC antiarrhythmic agent, should be
effective in treating patients who have paroxysmal supra-
ventricular reentrant tachycardia, because it affects con-
duction in the atrium, atrioventricular (AV) node, His-Pur-
kinje system and ventricle and thus can prevent tachycardia
by interfering with conduction in several places along the
reentrant circuit (1-6). Previously, our group (7) demon-
strated that propafenone is safe and effective for treating
patients who have refractory complex ventricular ectopic
rhythm.
We evaluated the effectiveness of intravenously admin-
From the Division of Cardiovascular Diseases and Internal Medicine,
Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
Manuscript received September 2, 1986: revised manuscript received
November 12, 1986, accepted December 12, 1986.
Address for reprints: Stephen C. Hammill, MD, Division of Cardio-
vascular Diseases and Intemal Medicine. Mayo Clinic, Rochester. Min-
nesota 55905.
© 1987 by the American College of Cardiology
tachycardia. Propafenone had no effect on blood pres-
sure, heart rate, PA interval, AV node refractoriness or
rate of reentrant tachycardia. Propafenone significantly
(p < 0.05) prolonged the AH, HV, QRS and ventricu-
loatrial intervals and decreased the AV node Wencke-
bach rate.
Of the nine patients receiving long-term oral pro-
pafenone therapy, eight had a reduction of at least 90%
in reentrant tachycardia during a mean follow·up period
of 14.5 months (range 11 to 22); all eight patients had
had noninducible reentrant tachycardia after intrave-
nous propafenone. One patient had increased frequency
of reentrant tachycardia; this patient had had inducible
reentrant tachycardia after intravenous propafenone.
In conclusion, intravenously administered propafen-
one terminated reentrant tachycardia in 85% of patients
and prevented reinduction in 71%, with no adverse
hemodynamic effects.
(J Am Coli CardioI1987;9:1364-8)
istered propafenone in terminating supraventricular reen-
trant tachycardia during electrophysiologic testing. We as-
sessed this agent's effect on the conduction properties of
the AV conduction system and its ability to prevent reentrant
tachycardia by programmed stimulation. We also reviewed
the long-term results in patients who received oral propa-
fenone therapy for control of reentrant tachycardia.
Methods
Study patients (Table 1). There were 14 patients (4
men and to women) with reentrant tachycardia refractory
to previous antiarrhythmic therapy. The mean age of the
patients was 50 years (range 28 to 69). Before electro-
physiologic testing, six patients had no associated cardiac
abnormality, five had Wolff-Parkinson-White syndrome, two
had symptomatic coronary artery disease and one had mitral
valve prolapse. Primary symptoms associated with the ar-
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Table l. Propafenone Therapy for Reentrant Supraventricular Tachycardia in 14 Patients
RT History Previous RT Response to Plasma
Age (yr) Cardiac (symptomatic Drugs Intravenous Propafenone
Case & Sex Disease episode/S rno) Failed Prupafenone Level (ng/ml)
AV Reentry. Bidirectional Accessory Pathway (WPW)
28M None 6 O.B Terminated: not 1.130
inducible
2 65F None 3 B. N. V.O. D No effect 1.430
3 olF None 3 D.P. V No effect 1.850
4 56F None 6 B Terminated: easily 1.160
inducible.
slower
5 28M None 26 D.O.P. V.B Terminated: not
inducible
AV Reentry , Retrograde Dilly (concealed accessory pathway )
6 48F None 120 D. B. V Terminated: not 630
inducible
7 30M None 12 D. O. P. V. B Terminated: nor 344
inducible
8 30F None 6 B.P.D. O. V Terminated: 793
inducible.
nonsustained
AV Node Reentry
9 64F None 26 D. V.N Terminated: not 2.520
inducible
10 69F CAD 26 D. B Terminated: not
inducible
II 32F MVP 100 D. V.N Terminated: not 670
inducible
12 64M CAD 104 O.B.D. V Terminated: not 441
inducible
13 65F None 26 V. B.D Terminated: not 1.847
inducible
14 65F None 120 A. V.N.D. B Terminated: not
inducible
Long-Term Treatment
(follow-up. response)
Surgical ablation
(21 mo. no RT)
Amiodarone
(2 1 mo. no RT)
Amiodarone
(20 mo. RT x 3)
Propafenone (discontinued
I mo. frequent RT)
Surgical ablation
(10 mo. no RT)
Propafenone
(14 mo. no RT)
Propafenone
( 14 mo. no RT)
Propafenone
(12 mo. RT x 1)
Propafenone
(22 mo. no RT)
D. B. CABG
(21 mo. RT x 2)
Propafenone
(19 mo. no RT)
Propafenone
(14 mo. RTx2)
Propafenone
( 12 mo. no RT)
Propafenone
(II mo. no RT)
A = amiodarone: AV = atrioventricular; B = beta-adrenergic blocking agent: CABG coronary artery bypass graft: CAD = coronary artery
disease: D = digoxin: MVP = mitral valve prolapse: N = disopyramide: P ~ procainarnide: 0 = quinidine; RT = reentrant tachycardia; V ,.
verapamil; WPW = Wolff-Parkinson-White syndrome.
rhythmia included palpitation q,Jtd weakness in seven pa-
tients. palpitation and light-headedness in four. angina in
two and syncope in one. Previous treatment had been at-
tempted with a mean of 3.5 (range I to 5) antiarrhythmic
agents that were either ineffective in controlling the reentrant
tachycardia or were poorly tolerated. The patients had been
unsuccessfully treated with digoxin (12 patients). l3-adre-
nergic receptor blockingagents (I I patients), verapamil ( I I
patients), quinidine (6 patients), procainamide (4 patients),
disopyramide (4 patients) and amiodarone (l patient).
Electrophysiologic testing. Electrophysiologic assess-
ment was performed after obtaining informed consent, as
reportedpreviously(8). All antiarrhythmic drug therapy was
discontinued at least five half-lives beforeelectrophysiologic
study. The following variables weredetermined in the base-
line state before the administration of propafenone or pla-
cebo: blood pressure, heart rate. PA interval, AH interval,
HV interval, QRS duration, heart rate at which AV node
Wenckebach conduction occurred. AV node effective re-
fractory period, accessory pathway effective refractory pe-
riod in the anterograde and retrograde directions, rate at
which I: I conduction was maintained over the accessory
pathway in the anterograde and retrograde directions and
the mean heart rate and shortest RR interval between pre-
excited beats during atrial fibrillation in patients with Wolff-
Parkinson-White syndrome. During reentrant tachycardia,
the following variables were assessed before drug admin-
istration: cycle length. AH interval, HV interval and ven-
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triculoatrial (VA) interval. The mechanism of the tachy-
cardia was determined to be due to reentry within the AV
node or utilization of a concealed or manifest accessory
pathway using standard criteria (1).
Study design. After determination of baseline variables,
reentrant tachycardia was initiated and observed for at least
10 minutes in each patient. All patients were given a 10
minute infusion of either propafenone (2 mg/kg) or placebo,
according to a double-blind, randomized, crossover coding
system. A second infusion was given only if the reentrant
tachycardia had not converted to sinus rhythm within 10
minutes of the first infusion. The reentrant tachycardia was
terminated by programmed stimulation at the first sign of
significant hemodynamic alteration or intolerable symp-
toms, or if 10 minutes had elapsed after the second infusion.
After termination of reentrant tachycardia, the previously
listed electrophysiologic variables were measured during
sinus rhythm, after the sinus rate had stabilized. The in-
duction of tachycardia was attempted using programmed
stimulation, which consisted of incremental atrial pacing,
the introduction of single and double premature atrial stimuli
during sinus rhythm and atrial pacing, incremental ventric-
ular pacing and the introduction of single ventricular stimuli
during ventricular pacing. If reentrant tachycardia could be
induced after the infusions, the electrophysiologic variables
were again measured. Pacing threshold was two times
threshold during baseline and after propafenone use.
Blood samples were drawn for measurements of plasma
propafenone at the end of each 10 minute infusion. After
the study, all patients were closely observed by electrocar-
diographic (ECG) monitoring for 24 hours, and routine lab-
oratory tests were obtained, including hemoglobin, hema-
tocrit, leukocyte count, liver function tests and serum
electrolytes, antinuclear antibody, creatinine, urea and crea-
tine kinase. All patients tolerated the propafenone well, and
complications were not observed. In addition, abnormalities
on routine laboratory testing or 24 hour monitoring were
not observed. Long-term treatment was determined by the
referring physician and was carried out with propafenone
in nine patients.
Statistics. Statistical analysis was performed using Stu-
dent's two-tailed t test for paired data, and a probability (p)
value of <0.05 was accepted as the limit of significance.
Results
There were five patients with Wolff-Parkinson-White
syndrome and an accessory pathway capable of bidirectional
conduction who had orthodromic AV reentrant tachycardia,
three patients with an accessory pathway capable of only
retrograde conduction (concealed accessory pathway) and
AV reentrant tachycardia and six patients with AV node
reentrant tachycardia.
Hemodynamic and conduction variables (Tables 2 and
3). Propafenone did not affect systolic or diastolic blood
pressure, heart rate during sinus rhythm, PA interval or heart
rate or AH interval during reentrant tachycardia. Propafen-
one significantly prolonged the following variables: rest AH
interval, HV interval and QRS duration; HV interval during
reentrant tachycardia; and VA interval during reentrant
tachycardia. Propafenone significantly reduced the heart rate
at which the Wenckebach conduction in the AV node oc-
curred.
Effect of propafenone on reentrant tachycardia (Ta-
ble 1). In five patients with Wolff-Parkinson-White syn-
drome and AV reentrant tachycardia, propafenone had no
effect on the reentrant tachycardia in two patients, but ter-
minated it in three; in one of these three the tachycardia
could be reinduced. In all three patients with AV reentrant
tachycardia utilizing a concealed accessory pathway, pro-
pafenone terminated the tachycardia. The tachycardia could
no longer be induced in two of the patients and could be
induced but was nonsustained in the other patient. In all six
patients with reentry in the AV node, propafenone termi-
nated the reentrant tachycardia, and in all six patients, the
tachycardia could not be reinduced.
Effect of propafenone on anterograde accessory path-
way conduction in Wolff-Parkinson-White Syndrome
(Table 3). In the five patients with Wolff-Parkinson-White
syndrome, propafenone completely blocked conduction over
the accessory pathway in two patients and decreased the
Table 2. Effect (mean ± SO) of Intravenously Administered
Propafenone on Electrophysiologic and Blood Pressure
Measurements in 14 Patients
Control Propafenone
Systolic blood pressure (mm Hg) 122 ± 19 120 ± 23
Diastolic blood pressure (mm Hg) 77±1O 76 ± 23
Heart rate (beats/min) 90 ± 19 87 ± 12
PA interval (ms) 32 ± 10 38 ± 13
AH interval (ms) 89 ± 25 100 ± 34*
HV interval (rns) 43 ± 6 57 ± 10*
QRS duration (ms) 79 ± 12 94 ± 14*
AV node Wenckebach rate 181 ± 36 145 ± 23*
(beats/min)t
AV node effective refractory 310 ± 74 345 ± 81
period (ms)
Atrial effective refractory period 229 ± 37 242 ± 54
(ms)
Ventricular effective refractory 229 ± 24 245 ± 28
period (ms)
Reentrant tachycardia
Heart rate (beats/min) 172 ± 7 144 ± 6
AH interval (rns) 196 ± 103 212 ± 104
HV interval (rns) 46 ± 7 53 ± 7*
Ventriculoatrial interval (ms) 106 ± 50 150 ± 71*
*Significantly different from control value (p < 0.05). tHeart rate at
which Wenckebach conduction occurred in the atrioventricular (AV) node.
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Table 3. Effect of Intravenous Propafenone on Electrophysiologic Measurements in Eight Patients With an Accessory
Atrioventricular Pathway
AV Reentry, Bidirectional Accessory Pathway (WPW)
AP-ERP (ms)
AP I: I Conduction
(beats/min)
Case
2
4
5
7
14
C(A/R)
330/260
<230/220
<260/<240
240/220
300/200
P (A/R)
B/B
<255/<235
<2601<270
3201-
BIB
C (A/R)
110/240
2701250
230/287
2301220
188/270
P (A/R)
BIB
230/188
2001250
1201176
B/B
Atrial Fibrillation
Shortest RR
Mean Rate Interval
(beats/min) (rns)
C P C P
120 NI 410 NI
176 160 365 360
180 150 180 230
133 NI 200 NI
144 144 NI NI
AV Reentry, Retrograde Only (concealed accessory pathway)
8
10
12
RT
<200
<220
B
<220
RT
300
230
B
167
A/R anterograde/retrograde; AP = accessory pathway; B = conduction absent; C control; ERP = effective refractory period; NI = not
inducible; P = propafenone; RT = reentrant tachycardia.
rate of 1:1 conduction over the pathway during atrial pacing
in three. Atrial fibrillation could not be induced in three of
the patients after propafenone administration, and in the
remaining two, the mean heart rate was slowed and the
shortest RR interval between pre-excited beats was pro-
longed by propafenone (Fig. 1).
Plasma propafenone levels (Table 1). The meanplasma
level of propafenone at the termination of tachycardia was
1,165 ng/ml (range 441 to 2,520). Patients who failed to
respond to propafenonedid not have a significantly different
plasma level from that of patients who did respond.
Figure 1. Top panel, Atrial fibrillation recorded by surface lead
VI ina patient with Wolff-Parkinson-White syndrome. Conduction
to the ventricle is over the accessory pathway and normal con-
duction system, resulting in aberrantly conducted QRS complexes
and normal QRS complexes. Bottom panel, Atrial fibrillation in
the same patient after intravenously administered propafenone.
Conduction over theaccessory pathway has been slowed, and most
of the impulses are conducted through the atrioventricular node
and His-Purkinje system, resulting in normal ventricular activa-
tion.
Long-term follow-up (Table 1). Nine patients received
long-term oral propafenone therapy, with dosage ranging
from 600 to 1,200 mg daily in three or four divided doses
(median dosage 300 mg 3 times daily). Eight patients had
a reduction of :::::90% in symptomatic episodes of reentrant
tachycardiaduring a mean follow-up period of 14.5 months
(range lito 22). After intravenous propafenone therapy,
reentrant tachycardia could not be induced during electro-
physiologic testing in these eight patients. The ninth patient
(Case 4) experienced an increase in the frequency of reen-
trant tachycardia episodes, and the use of propafenone was
discontinued after 1 month. This patient's reentrant tachy-
cardia was inducible after intravenous propafenone therapy
during e1ectrophysiologic testing.
The remaining five patients who did not receive propa-
fenone had the following therapy: two patients had surgical
division of their accessory pathway with no recurrence of
reentranttachycardiaduring 10and 2I months, respectively;
two patients received amiodarone therapy and had a reduc-
tion of :::::90% in the frequency of reentrant tachycardia
during 21 months (both patients failed to respond to intra-
venous propafenone therapy during eiectrophysiologic test-
ing); and the final patient underwentcoronary artery bypass
grafting for control of refractory angina, and her reentrant
tachycardia was treated with digoxin and propranolol after
she had refused oral propafenone therapy. This patient has
had two episodes of reentrant tachycardia and required con-
version of the arrhythmia in the emergency room.
Side effects. During long-term follow-up, the side ef-
fects associated with propafenone included headache in one
patient and fatigue and nausea in one; the other six patients
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did not experience side effects. None of the side effects
required discontinuing propafenone use.
Discussion
Intravenously administered propafenone terminated reen-
trant tachycardia in 12 (85%) of 14 patients and prevented
the reinduction of reentrant tachycardia in 10 (71%); there
were no adverse hemodynamic effects or other evidence of
toxicity. As has been documentedpreviously (7,9), the plasma
level of propafenone varied widely and was not predictive
of which patient would respond to intravenous propafenone
therapy.
Effect of propafenone on conduction. Propafenone
slowed conduction through the AV node (AH interval),
through the His-Purkinje system (HV interval and QRS com-
plex) and over the accessory pathway (VA interval). This
result was consistent with propafenone's class IC effect
(2, 10). Propafenone slowed the rate of reentrant tachycardia
from 172 ± 7 to 144 ± 6 beats/min just before termination,
although this decrease was not statistically significant (p =
0.06).
Propafenone terminated reentrant tachycardia in all six
patients with AV node reentrant tachycardia by slowing the
conduction in the retrograde limb of the reentrant circuit
(significant prolongation of the VA interval).
Propafenone for Wolff-Parkinson-White syndrome.
Patients with Wolff-Parkinson-White syndrome are at risk
for reentrant tachycardia and atrial fibrillation, during which
they may experience rapid anterograde conduction over the
accessory pathway, resulting in a rapid ventricular response
and hemodynamic compromise (11). As demonstrated in
this and in previous studies (5), a class IC antiarrhythmic
drug such as propafenone can terminate reentrant tachycar-
dia in patients with Wolff-Parkinson-White syndrome by
altering conduction in both the AV node and the accessory
pathway and thus affecting both limbs of the reentrant cir-
cuit. This drug is also effective in controlling the ventricular
response during atrial fibrillation by slowing the conduction
in the anterograde direction over the accessory pathway.
In our study, the patients with Wolff-Parkinson-White
syndrome had an accessory pathway with relatively long
anterograde refractoriness and slow anterograde conduction.
Patients with Wolff-Parkinson-White syndrome and an ac-
cessory pathway that demonstrates short refractoriness and
rapid conduction may not be affected significantly by pro-
pafenone, as has been reported with procainamide, but this
requires investigation (12).
Long-term oral therapy with propafenone. Propafen-
one was effective and well tolerated in eight of the nine
patients in whom it was used as long-term therapy. In these
eight patients, reentrant tachycardia could not be induced
after propafenone was administered, whereas in the patient
in whom long-term propafenone therapy was not effective,
sustained reentrant tachycardia was easily induced after pro-
pafenone was administered during the electrophysiologic
study. This finding is consistent with previous data (13)
indicating that the response to programmed stimulation dur-
ing intravenous propafenone therapy in patients with reen-
trant tachycardia will predict their long-term response to
oral propafenone therapy.
Conclusions. Intravenous propafenone therapy is effec-
tive for terminating reentrant tachycardia, and oral propa-
fenone therapy is effective for the long-term treatment of
patients with such tachycardia. In patients with Wolff-Par-
kinson-White syndrome, intravenous propafenone therapy
is effective for both terminating the reentrant tachycardia
and controlling the ventricular rate during atrial fibrillation.
The drug seems to be well tolerated, and no significant
adverse hemodynamic effects are noted when the drug is
given intravenously.
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